Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Seres Therapeutics Inc. MCRB

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing... see more


Bullboard (NDAQ:MCRB)

View:
User Avatar Image
(0)
•••
  • IvanIvanX
Post by IvanIvanon Apr 27, 2023 3:34am

Price

In December 2020, when SER-109 passed phase 3, the price rose to $38. Expect it to be at that price again in a month. Analysts will increase the target price after FDA approval.
Post by hoffbagon Jan 15, 2023 2:06pm

Maybe a chance to accumulate

Below 5 again. Maybe right cap on approval is between 800 - 900 million? 
Post by hoffbagon Oct 31, 2022 5:10pm

Popping now!

Target valuation getting closer. 
Post by hoffbagon Sep 08, 2022 3:13pm

Patience cont….

Now over 6. 
Post by hoffbagon Aug 19, 2022 7:17pm

Patience and intestinal fortitude

Now over 5. 
Post by hoffbagon Jun 08, 2022 2:20pm

SER 109

The time has come.  BLA approval has a higher probability.  Potential multi-bagger. Last traded this on the run from 4 to 20 in 2020.  Lets have a repeat please.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >